{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-038998","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.431056+00:00","generated_at":"2026-06-09T03:22:48.918955+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mangoceuticals receives Nasdaq bid-price deficiency notice; 180 days to cure","bullets":["Received Nasdaq notice on Oct 30, 2023 for failing $1.00 minimum bid price for 30 consecutive business days.","Has until April 29, 2024 to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, may qualify for a second 180-day cure period if other listing criteria are met.","Company plans to monitor bid price and may consider a reverse stock split to regain compliance.","No immediate impact on Nasdaq listing; delisting risk if deficiency not cured within timelines."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-038998","json":"https://secwatch.observer/filing/0001493152-23-038998.json","markdown":"https://secwatch.observer/filing/0001493152-23-038998.md","text":"https://secwatch.observer/filing/0001493152-23-038998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223038998/0001493152-23-038998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223038998/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:22:48.918955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fefd3e274a65a2c899d5fd7b3846350e2585238","claim":"MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"October 30, 2023, Mangoceuticals, Inc. (the “Company”) received written notice (the “ Notification Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315223038998/0001493152-23-038998-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}